Eu cryptate-labeled anti-GST antibody for capturing GST-tagged proteins in protein/protein interaction assays.
For research use only. Not for use in diagnostic procedures.
Feature | Specification |
---|---|
Application | Protein-Protein Interaction |
Eu cryptate-labeled anti-GST antibody for capturing GST-tagged proteins in protein/protein interaction assays.
For research use only. Not for use in diagnostic procedures.
MAb Anti GST-Eu cryptate is an IgG2a raised against Glutathione S-transferase labeled with Eu. It has been shown to react with GST-tagged fusion proteins from a large number of expressing vectors.
This reagent can be used in both biochemical and cellular formats to study a wide variety of interactions: protein/protein, protein/peptide, protein/DNA, protein/RNA, protein/carbohydrate, protein/small molecule, receptor/ligand.
HTRF can detect a broad range of affinity constants ranging from picomolar to low millimolar.
Application |
Protein-Protein Interaction
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Fluorescent Reagent
|
Shipping Conditions |
Shipped Ambient
|
Target Class |
Binding Assay
|
Technology |
TR-FRET
|
Therapeutic Area |
Cardiovascular
Infectious Diseases
Inflammation
Metabolism/Diabetes
NASH/Fibrosis
Neuroscience
Oncology & Inflammation
Rare Diseases
|
Unit Size |
5,000 Assay Points
|
In an HTRF interaction assay, one partner is labeled (directly or indirectly) with the donor, and the other with the acceptor (again, directly or indirectly). The intensity of the signal is proportional to the binding of the 2 partners. In the example shown here: MAb Anti GST-Eu cryptate binds to the GST tagged partner A while partner B* binds to a specific Ab labeled with an HTRF acceptor. *partner B can also be biotinylated, tagged, Fc fused. In these cases, use the corresponding HTRF reagent (anti-Tag, anti-species, protA, Streptavidin) labeled with acceptor for the detection.
The example on the right describes the protocol using a 20 µL final assay volume for detecting an interaction between a GST-tagged partner A and a non-tagged partner B*. Dispense the 2 partners (10 µL), incubate, add MAb Anti GST-Eu cryptate (5 µL) and anti-partner B labeled with acceptor (5 µL), incubate and read. *partner B can also be biotinylated, tagged, Fc fused or directly labeled. In these cases, use the corresponding HTRF reagent (anti-Tag, anti species, protA, Streptavidin) labeled with acceptor for the detection.
The average conjugate quantity per well reflects overall biological material content. Using the active moiety amount is generally preferred to the quantity of total conjugate. For Cryptate and d2 conjugates, the total conjugate amount equals that of the active moiety, since the molecular weight of the label is negligible. This is not the case for XL665 labeled entities for which the quantity of total conjugate will vary depending on the final molar ratio of the XL665 conjugate, however, the amount of active moiety, provided by Revvity, is constant and based on the number of tests ordered.
Cryptate conjugates must not be excessive in order to prevent reader saturation and an unacceptable level of background. In most cases, a cryptate concentration of 1 to 5nM is appropriate, and will generate 20,000 to 80,000 cps at 620 nm depending on the HTRF compatible reader used. The XL665 conjugate must match its assay counterpart as closely as possible in order for the maximum number of biomolecules to be tagged with the XL665 acceptor. Thus, to detect a tagged molecule at an assay concentration of 20nM, the concentration of anti-Tag-XL665 should be equimolar or higher.
p53, a tumor suppressor protein activated in response to DNA damage, is regulated by the binding of HDM2 which induces ubiquitin-medicated degradation of p53. Our HTRF assay was developed to monitor p53/HDM2 binding, to assess the effect of serine phosphorylation within the p53 N-terminus on HDM2 binding, and to determine the relative affinity of a p53 homologue, p73, for HDM2. This assay employs a site-specific biotinylated p53 protein, a GST-fused HDM2 protein, streptavidin-XL665 and europium cryptate-labeled anti-GST antibody. Kane et al. - Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal Biochem. 2000;278: 29-38.
Are you looking for resources, click on the resource type to explore further.
A Bruton Tyrosine Kinase (BTK) case study
PROteolysis Targeting Chimeras (PROTACs) are one of the latest trending tools used in...
Challenge large complexes with HTRF assays
This note describes how to investigate small- to large protein-protein interaction...
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
HTRF assays to assess PROTAC® compounds
Kinases constitute about 2% of all human genes and are essential proteins involved in...
Get up to speed with the latest developments on PROTAC® design and verification.
Harnessing the power of the cellular protein and...
We are here to answer your questions.